a healthcare automation company focused on robotic and imaging systems for cancer diagnostics, has raised $5 million in a Series A round led by Inflexor Ventures.
The funding will enable the Bengaluru-based company to accelerate global market expansion, scale manufacturing for its flagship products RoboTome and MorphoLens, invest in global regulatory approvals, and deepen its technology and IP leadership as it expands into major international markets.
Founded in 2017, Morphle Labs works in the area of histopathology automation—an essential but traditionally manual part of cancer diagnostics. While fields such as radiology and hematology have seen significant digitisation, anatomic pathology still depends heavily on labour-intensive processes. Many labs globally face technician shortages and growing case backlogs. Morphle aims to streamline these workflows using robotics, precision hardware, optics and computer vision.
“Our vision at Morphle is to rethink healthcare from the ground up. Histology remains one of the few critical domains still untouched by true automation, and that is where we have chosen to start. With RoboTome and MorphoLens, we have tackled two of the most challenging bottlenecks in diagnostics, high-throughput robotic microtomy and robust, modular slide imaging, but this is only the beginning. The larger opportunity lies in stitching together every broken link in the diagnostics chain, enabling labs to deliver faster, higher-quality results and empowering pathologists to focus on what matters most: the diagnosis,” Rohit Hiwale, Founder & CEO, Morphle Labs, said.
“With this funding we will also be expanding our team, While solving some extremely valuable problems for mankind, we are on a mission to improve talent density across Robotics & computer vision,” he added.
The company’s flagship platform, RoboTome, is a robotic microtome designed to automate the slicing of biopsy blocks, offering faster and more consistent sectioning compared to traditional manual methods. Its companion product, MorphoLens, is a slide scanner that can digitise over 100 slides per hour using integrated optics and imaging technology, supporting remote pathology and higher-volume lab operations.
Together, the two systems aim to streamline some of the more complex and manual steps in histology, improving workflow speed and reliability. Morphle has also filed more than 80 patents across robotics, optics, embedded systems, and imaging.
“Morphle Labs is transforming one of the most overlooked yet mission-critical segments of global healthcare. Their ability to bring together robotics, imaging, and AI into clinically reliable systems is exceptional. The traction they are already seeing with leading labs in the U.S. and Europe demonstrates both the scale of the problem and Morphle’s ability to solve it. We believe they are poised to become a global leader in tissue diagnostics automation, and we are excited to support their journey,” added Pratip Mazumdar, Partner at Inflexor Ventures.
(Edited by Affirunisa Kankudti)
Original source: in